A Study of Relation between Plasma Level of Insulin-like Growth Factor-1 (IGF-1) and Severity of Coronary Artery Disease

Document Type : Research Paper


1 Assistant Professorof Cardiology, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran

2 Associate Professor of Cardiology, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran

3 Resident of Internal Medicine of Cardiology, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran

4 General Practitioner of Afzalipour Hospital, KermanUniversity of Medical Sciences, Kerman, Iran


Atherosclerosis and its related diseases are major causes of mortality in many countries. Our knowledge of its background is of much importance. In recent years, researches have been preformed on relation between atherosclerosis and IGF-I plasma levels and different results obtained. We decided to do this research, as few studies have been done in this field in our country.
Materials and Methods
Altogether One hundred and seven patients who were candidates for the coronary angiography were chosen for study. Blood samples were taken for measuring IGF-I, FBS, triglyceride, total cholesterol, LDL and HDL in plasma. Blood pressures of patients were recorded, and their BMIs accounted. It was also written in questionnaire if they had history of cigarette smoking.
IGF-I plasma levels increased in relation to intensity of coronary artery stenosis; correlation coefficient between stenoses and IGF-I plasma levels was as follows: R= 0.204 p= 0.04. This suggested significant and meaningful relation between these variables. IGF-I plasma levels also showed mild increase in relation to number of diseased coronary arteries. By using the analysis of spierman correlation coefficient, Rho= 0.189 and p= 0.058 were accounted.
We concluded that IGF-I plasma levels were in direct and meaningful relation to stenosis values of coronary arteries, and in mild relation to number of diseased coronary arteries. These findings can explain the role of IGF-1 in process of atherosclerosis.


1- Clemmous David R. Physiology of Insulin-like Growth factor I. In uptodate 16.3. Available at:
2- Plengpanich W, Mangkala J, Buranasukajorn P, Boonruang K, Sunthornyothin S, Suwanwalaikorn S, et al.
Normal Refrence Range of serum insulin – like Growth factor ( IGF) –I in healthy thai Adults. J med Assoc Thai
2008; 91:1681-1684.
3- Perticone F, Sciacqua A, Perticone M, Laino I, Miceli S, Care` I, et al. Low-plasma insulin-like growth factor -1
levels are associated with impaired endothelinum-dependent vasodilatation in a cohort of untreated,hypertensive
Caucasian subjects. J Clin Endocrinol Metab 2008; 93:2806-2810. Epub 2008 Apr 22
4- Brevetti G, Colao A, Schiano V, Pivonello R, Laurenzano E, Di Somma C, et al. IGF system and peripheral
arterial disease:relationship with disease severity and inflammatory status of the affected limb. Clin
Endocrinol(Oxf) 2008; 69:894-900 .Epub 2008 Apr 10.
5- Kawachi S, Takeda N, Sasaki A, Kokubo Y, Takami K, Sarui H, et al. Circulating Insulin-like growth factor-1
and Insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler
Thromb Vasc Biol 2005; 25:617-621. Epub 2004 Dec 29.
6- Martin RM, Gunnell D, Whitley E, Nicolaides A, Griffin M, Georgiou N, et al. Association of insuline-like
growth factor(IGF)-1, IGF-2, IGF binding protein(IGFBP)-2 and IGFBP-3 with ultrasound measures of
atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab 2008; 93:1331-1338.
Epub 2008 Jan 22.
7- Lawlor DA, Ebrahim S, Smith GD, Cherry L, Watt P, Sattar N. The association of insulin-like growth factor
1(IGF-1) with incident coronary heart disease in women:Findings from the prospective British Women`s Heart and
Health Study. Atherosclerosis 2008; 201:198-204. Epub ahead of print.
8- Laura A. ColangeloI, Kiang Liu1, Susan M. Gapstur. Insulin-like growth factor-1, Insulin-like growth factor
binding protein-3, and cardiovascular disease risk factors in young black men and white men. Am J Epidemiol
2004; 160:750–757.
9- Abbas A, Grant PJ, Kearney MT. Role of IGF-1 in glucose regulation and cardiovascular disease. Expert Rev
Cardiovascular Ther 2008; 6:1135-1149.
10- Ostadrahimi A, Moradi T, Zarghami N, Shoja MM. Correlates of serum leptin and insulin- like growth factor-1
concentrations in normal weight and overweight/obese Iranian woman. J Womens Health (Larchmt) 2008; 17:1389-1397.
11- Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, et al. IGF-1 reduces inflammatoy
responses, suppresses oxidative stress, and decreases Atherosclerosis progression in Apo E deficient mice.
Arteioscler throm b Vasc Biol 2007; 27:2684- 2690.
12- Ruiz Torres A. The role of Insulin – Like growth factor 1 and insulin in aging and atherosclerosis. Novartis
Founal symp 2002; 242:143-153;discussion 153-60.
13- Ukkola o, Poykko S, Paivansalo M, Kesaniemi YA. Interactions between ghrelin, leptin and IGF –I affect
metabolic syndrome and early Atherosclerosis .Ann med 2008; 40: 465-473.
14- Saleem T, Mohammad KH, Abdel-Fattah MM, Abbasi AH. Association of glycosylated haemoglobin level
and diabetes mellitus duration with the severity of coronary artery disease. Diab Vasc Dis Res 2008; 5:184-189.
15- Akanji AO, Suresh CG, Al-Radwan R, Fatania HR. Insulin-like growth factor (IGF)-I, IGF-II and IGFbinding
protein (IGFBP)-3 levels in Arab subjects with coronary heart disease. Scand J Clin Lab Invest 2007;
16- Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low serum insulin-like growth factor I is
associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002;
106: 939–944.
17- Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, et al. Association of total insulinlike
growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident
coronary events and ischemic stroke. J Clin Endocrinol Metab 2007; 92:1319-1325.
18- Unden AL, Elofsson S, Knox S, Lewitt MS, Brismar K. IGF-I in a normal population: relation to psychosocial
factors. Clin Endocrinol (Oxf) 2002; 57:793-803.
19- Sierra – Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Mälarstig A, Brismar K, Hamsten A, et al. IGF
–I / IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clin Sci (Lond) 2009; 116:507-512.